Second-line drug treatment in rheumatoid arthritis associated with depressed autologous mixed lymphocyte reaction

1986 ◽  
Vol 6 (1) ◽  
pp. 25-29 ◽  
Author(s):  
G. S. Panayi ◽  
M. McKenzie Mills
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Treatment ◽  
Mixed Lymphocyte Reaction ◽  
Second Line ◽  
Autologous Mixed Lymphocyte Reaction ◽  
Line Drug

scholarly journals Real-world systemic therapy treatment patterns for squamous cell carcinoma of the head and neck in Canada

2019 ◽  
Vol 26 (2) ◽  
Author(s):  
K. Byrne ◽  
P. Hallworth ◽  
A. Abbas Tahami Monfared ◽  
A. Moshyk ◽  
J. W. Shaw
Keyword(s):  
Squamous Cell Carcinoma ◽  
Clinical Practice ◽  
Drug Treatment ◽  
Real World ◽  
Treatment Patterns ◽  
Line Treatment ◽  
Second Line ◽  
First Line ◽  
Line Drug ◽  
First Line Treatment

Background In the present study, we examined real-world treatment patterns for squamous cell carcinoma of the head and neck (scchn) in Canada, which are largely unknown.Methods Oncologists across Canada provided data for disease history, characteristics, and treatment patterns during May–July 2016 for 6–8 consecutive patients receiving first-line or second-line drug treatment for scchn (including locally advanced and recurrent or metastatic disease).Results Information from 16 physicians for 109 patients receiving drug treatment for scchn was provided; 1 patient was excluded from the treatment-pattern analysis. Median age in the cohort was 63 years [interquartile range (iqr): 57–68 years], and 24% were current smokers, with a mean exposure of 26.2 ± 12.7 pack–years. The most common tumour site was the oropharynx (48%). Most patients (84%) received platinum-based regimens as first-line treatment (44% received cisplatin monotherapy). Use of cetuximab-based regimens as first-line treatment was limited (17%). Of 53 patients receiving second-line treatment, 87% received a first-line platinum-based regimen. Median time between first-line treatment with a platinum-based regimen and initiation of second-line treatment was 55 days (iqr: 20–146 days). The most common second-line regimen was cetuximab monotherapy (43%); platinum-based regimens were markedly infrequent (13%).Conclusions Our analysis provides real-world insight into scchn clinical practice patterns in Canada, which could inform reimbursement decision-making. High use of platinum-based regimens in first-line drug treatment was generally reflective of treatment guidelines; cetuximab use in the second-line was higher than anticipated. Additional real-world studies are needed to understand the effect of novel therapies such as immuno-oncology agents on clinical practice and outcomes, particularly for recurrent or metastatic scchn.

Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru

The Lancet ◽  
2002 ◽  
Vol 359 (9322) ◽  
pp. 1980-1989 ◽  
Author(s):  
Pedro G Suárez ◽  
Katherine Floyd ◽  
Jaime Portocarrero ◽  
Edith Alarcón ◽  
Elisabetta Rapiti ◽  
...  
Keyword(s):  
Cohort Study ◽  
Cost Effectiveness ◽  
Drug Treatment ◽  
Second Line ◽  
Tuberculosis Patients ◽  
National Cohort ◽  
Line Drug

Second-Line Drug Therapy for Rheumatoid Arthritis

1994 ◽  
Vol 330 (19) ◽  
pp. 1368-1375 ◽  
Author(s):  
Alastair J.J. Wood ◽  
Joseph M. Cash ◽  
John H. Klippel
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Therapy ◽  
Second Line ◽  
Line Drug

PRODUCTION OF INTERLEUKIN-6 BY MONOCYTES ISOLATED FROM RHEUMATOID ARTHRITIS PATIENTS RECEIVING SECOND-LINE DRUG THERAPY

Rheumatology ◽  
1994 ◽  
Vol 33 (9) ◽  
pp. 821-825 ◽  
Author(s):  
A. CRILLY ◽  
R. MADHOK ◽  
J. WATSON ◽  
H. A. CAPELL ◽  
R. D. STURROCK
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Therapy ◽  
Interleukin 6 ◽  
Second Line ◽  
Line Drug
Sign in / Sign up

Export Citation Format

Share Document